CT and PET/CT fusion for lung cancer biopsy planning

Cherkashin, Mikhail; Aniskhin, Mikhail; Berezina, N. A.; Пучков, Д. К.

doi:10.1136/bcr-2017-221972

Cited by 3 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, ultrasound, positron emission tomography-computed tomography (PET/CT) and magnetic resonance imaging have been applied for diagnosing human cancer (18). Notably, PET/CT has become an efficient protocol for tumor diagnosis in human lung cancer cases (19)(20)(21). PET/CT also serves a vital role in the differentiation of adrenal metastasis from a benign adrenal mass in patients with lung cancer, with excellent diagnostic…”

Section: Introductionmentioning

confidence: 99%

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

et al. 2019

View full text Add to dashboard Cite

Positron emission tomography-computed tomography (PET/CT) is an efficient method for the diagnosis of various types of human cancer. Studies have demonstrated that Gd 2 O 3-doped carbon-11-choline (GdCho) can be used as a contrast nanoparticle for PET/CT in the diagnosis of patients with lung cancer. The aim of the present study was to evaluate the effect of GdCho-lenvatinib nanoparticles contrast-PET/CT (GdCho-Len-PET) in the diagnosis and treatment planning of a cohort of patients suspected of having lung cancer. The results of the present study demonstrated that GdCho-Len could be used as an efficient PET/CT contrast agent for the diagnosis of patients with lung cancer. GdCho-Len nanoparticles contrast agent exhibited a significantly improved longitudinal relaxivity compared with GdCho. The outcomes of the present study were that GdCho-Len-PET diagnosed 152 patients with lung cancer, whereas GdCho-PET diagnosed 130 patients with lung cancer among the 172 patients. GdCho-Len-PET presented with higher accuracy and sensitivity compared with GdCho-PET in diagnosing patients with lung cancer. All patients were further confirmed via histological analysis. GdCho-Len-PET contributed to the anticancer treatments in 56 out of 62 (90.3%) patients with lung cancer who were candidates for radiation therapy, 52 out of 57 (91.2%) patients with lung cancer undergoing adjuvant radiotherapy, and 13 out of 17 (76.5%) patients with lung cancer undergoing comprehensive therapy. Patients diagnosed using GdCho-Len-PET improved the survival of patients with lung cancer during a 420-day follow up. In conclusion, GdCho-Len-PET increased the diagnostic efficacy and had a significant effect on survival for patients with lung cancer, and may therefore serve as a reliable method for human cancer diagnosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

The Development and Application of PET/CT Imaging in Lung Cancer Diagnosis: A Review

Yang,

Sun,

Deng

et al. 2023

2023 7th Asian Conference on Artificial Intelligence Technology (ACAIT)

View full text Add to dashboard Cite

Multimodality Attention-Guided 3-D Detection of Nonsmall Cell Lung Cancer in ¹⁸F-FDG PET/CT Images

Chen

Liu

Shen

et al. 2022

IEEE Trans. Radiat. Plasma Med. Sci.

View full text Add to dashboard Cite

CT and PET/CT fusion for lung cancer biopsy planning

Cited by 3 publications

References 2 publications

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

The Development and Application of PET/CT Imaging in Lung Cancer Diagnosis: A Review

Multimodality Attention-Guided 3-D Detection of Nonsmall Cell Lung Cancer in ¹⁸F-FDG PET/CT Images

Contact Info

Product

Resources

About

CT and PET/CT fusion for lung cancer biopsy planning

Cited by 3 publications

References 2 publications

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

The Development and Application of PET/CT Imaging in Lung Cancer Diagnosis: A Review

Multimodality Attention-Guided 3-D Detection of Nonsmall Cell Lung Cancer in 18F-FDG PET/CT Images

Contact Info

Product

Resources

About

Multimodality Attention-Guided 3-D Detection of Nonsmall Cell Lung Cancer in ¹⁸F-FDG PET/CT Images